Gastroenterology Hepatology and Digestive System

Systematic Review



Correlation of Steatosis Degree With Metabolic Syndrome in Patients With Fatty Liver Disease Associated Metabolic Dysfunction (MAFLD)

Jonny Wafom[1], Fardah Akil[1,2], Muh. Ilyas[1,2], Syakib Bakri[1,2], Agus Sudarso[1,2], Arifin Seweng[3]

[1]Department of Internal Medicine, Faculty Of Medicine University of Hasanudin Makasar, Indonesia
[2]Dr. Wahidin Sudirohusodo Hospital Makassar, South Celebes, Indonesia
[3]Departemen Of Public Health and Community Medicine, Faculty of Medicine, University of Hasanudin Makasar, Indonesia.

Correspondence

Jonny Wafom

Department of Internal Medicine, Faculty of Medicine University of Hasanudin Makasar, Indonesia

- Received Date: 03 July 2025
- Accepted Date: 15 Dec 2025
- Publication Date: 02 Jan 2026

Keywords

Fatty liver disease, Steatosis, Metabolic Syndrome

Copyright

© 2026 Science Excel. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Abstract

Background: Metabolic-associated fatty liver disease (MAFLD) is a growing global health issue, frequently linked with metabolic syndrome—a cluster of conditions including obesity, insulin resistance, and hypertension. Hepatic steatosis, or fat accumulation in the liver, is a hallmark of MAFLD. Understanding the relationship between the severity of steatosis and metabolic syndrome components is crucial for risk stratification and treatment planning.

Objective: To evaluate the correlation between hepatic steatosis severity and the presence of metabolic syndrome and its individual components in patients diagnosed with MAFLD.

Methods: This cross-sectional analytical study was conducted at Dr. Wahidin Sudirohusodo General Hospital, Makassar, Indonesia, from 2024 to 2025. A total of 126 adult patients with confirmed MAFLD were recruited via consecutive sampling. Clinical and metabolic data were collected, including BMI, waist circumference, blood pressure, lipid profile, fasting glucose, and HbA1c. Hepatic steatosis was graded (1–3) based on imaging findings. Statistical analysis employed the Chi-square test with significance set at $p < 0.05$.

Results: Obesity (82.5%) and elevated waist circumference (93.7%) were highly prevalent, with 75.4% of subjects meeting criteria for metabolic syndrome. Grade 1 steatosis was most common (79.4%), followed by grades 2 (13.5%) and 3 (7.1%). Significant associations were found between steatosis severity and BMI ($p = 0.031$), hypertension ($p = 0.011$), and metabolic syndrome ($p = 0.021$).

Conclusion: The severity of hepatic steatosis is significantly associated with obesity, hypertension, and metabolic syndrome in MAFLD patients. These findings highlight the need for comprehensive metabolic risk management in this population.

Background

Hepatic steatosis, or steatosis or fatty liver, is a pathological condition characterized by the intracellular accumulation of lipids, predominantly triglycerides, within hepatocytes. It is defined by intrahepatic fat constituting at least 5% of the liver's weight. It is considered an early indicator of a range of liver pathologies, including non-alcoholic fatty liver disease (NAFLD). Although steatosis is potentially reversible, persistent lipid accumulation can progress to hepatic inflammation (steatohepatitis), fibrosis, cirrhosis, or even hepatocellular carcinoma if not appropriately managed [1].

Metabolic Associated Fatty Liver Disease (MAFLD) a recently adopted nomenclature replacing NAFLD, currently affects approximately 25% of the global adult population and represents a significant clinical and economic burden worldwide [2]. The increasing burden of MAFLD is closely related to rapid changes in lifestyle patterns, including decreased physical activity, high-energy intake, and the overall consumption of nutritionally unbalanced diets.[3] The new definition focuses on inclusive diagnostic criteria according to metabolic dysfunction presence rather than exclusion of significant alcohol consumption [4].

Data gathered from the Third National Health and Nutrition Examination Survey (NHANES III), encompassing 13,083 participants, indicate that the diagnostic criteria for MAFLD are more practical and demonstrate greater efficacy in identifying individuals at elevated risk than the former NAFLD framework [2,5]. Furthermore, several large-scale, population-based studies have reported a marked and exponential increase in the prevalence of MAFLD across the Asia-Pacific region over the last three decades [2].

A comprehensive systematic review and meta-analysis including 13,044,518 individuals from Asian populations estimated

Citation: Wafom J, Akil F, Muh I, Bakri S, Sudarso A, Seweng A. Correlation of Steatosis Degree With Metabolic Syndrome in Patients With Fatty Liver Disease Associated Metabolic Dysfunction (MAFLD). Gastroenterol Hepatol Dig Sys. 2026;3(1):2602.

the overall prevalence of MAFLD to be 29.62%. A complex interplay of genetic factors, dietary patterns, physical activity, lifestyle habits, and behavioral determinants modulates this figure. A meta-analysis of 18 studies estimated an annual MAFLD incidence of 50.9 cases per 1,000 individuals in Asian countries [5]. In Indonesia, prevalence rates have reached as high as 65.8% within specific subpopulations [6].

Research has demonstrated that individuals exhibiting higher grades of hepatic steatosis (grades 2 and 3) are more likely to present with key components of metabolic syndrome, including obesity, hypertension, insulin resistance, and dyslipidemia. Notably, MAFLD shares overlapping clinical characteristics with metabolic syndrome and is increasingly recognized as a condition fundamentally driven by insulin resistance [7]. Jinjuvadia et al. reported a 43% increase in NAFLD prevalence among individuals diagnosed with metabolic syndrome [8].

One of the main challenges in the clinical care of MAFLD is the identification of patients at risk for early progression to advanced disease stages. Surmounting this challenge includes comprehensive insight into intrahepatic and extrahepatic drivers of disease progression and the creation and implementation of valid, non-invasive diagnostic assays with high sensitivity and specificity [4].

Several investigations have consistently identified hepatic steatosis as an independent risk factor for the evolution of hepatic fibrosis, a significant prognostic factor in MAFLD patients. In addition, the degree of steatosis has also been shown to influence treatment outcomes and responses to medical treatment [9].

In light of these findings, it is important to evolve a more subtle understanding of the interaction between the degree of hepatic steatosis and liver disease progression to direct the development of more effective prevention, diagnostic, and therapeutic strategies [9,10].

Aim

This study aims to examine the correlation between the severity of hepatic steatosis and metabolic syndrome among patients diagnosed with Metabolic Associated Fatty Liver Disease (MAFLD).

Methods

This study employs an analytical correlational design with a cross-sectional approach and was conducted at Dr. Wahidin Sudirohusodo General Hospital, Makassar, Indonesia, throughout 2024 to 2025. The study population comprised all patients diagnosed with Metabolic Associated Fatty Liver Disease (MAFLD) at the institution during the study period. Participants were selected based on the following inclusion criteria: (1) age over 18 years, (2) confirmed diagnosis of hepatic steatosis or fatty liver through imaging or other diagnostic modalities, and (3) fulfilment of the diagnostic criteria for MAFLD. A minimum sample size of 73 individuals was determined, and participants were recruited using a consecutive sampling method, whereby eligible individuals were enrolled continuously until the required sample size was achieved.

Ethical approval for this study was obtained from the Biomedical Research Ethics Committee on Human Subjects, Faculty of Medicine, Hasanuddin University (Approval No.: 930/UN4.6.4.5.31/PP36/2024). Informed consent was obtained from all participants prior to data collection. Data analysis was performed using SPSS version 25, incorporating descriptive and inferential statistical methods. Descriptive statistics were utilized to summarize the demographic and clinical characteristics of the study population, including mean values, standard deviations, and frequency distributions. Inferential analysis was conducted using the Chi-square test to evaluate associations between variables, with statistical significance defined as a p-value of less than 0.05. The results are presented in narrative form and are supported by tables and figures for comprehensive interpretation.

Results

A total of 126 individuals diagnosed with MAFLD were enrolled in this study, comprising both inpatients and outpatients at Dr. Wahidin Sudirohusodo General Hospital during the period from November 2024 to March 2025. The participants ranged in age from 24 to 78 years, with a mean age of 51. Females represented 54.8% of the sample, while

Table 1. *Demographic and Clinical Characteristics*

Variable		n	%
Sex	Male	57	45,2
	Female	69	54,8
Age	<60 year-old	93	73,8
	>= 60-year-old	33	26,2
BMI	Obese	104	82,5
	Non Obese	22	17,5
Waist Circumference	High Risk	118	93,7
	Low Risk	8	6,3
Blood Pressure	Hypertension	73	57,9
	Non-hypertension	53	42,1
TG	High Risk	68	54,0
	Low Risk	58	46,0
HDL	High Risk	55	43,7
	Low Risk	71	56,3
FBG	Normal	57	45,2
	Pre diabetic	28	22,2
	Diabetic	41	32,5
DM	Yes	59	46,8
	No	67	53,2
HbA1c	Normal	52	41,3
	Pre-diabetic	20	15,9
	Diabetic	54	42,9
Steatosis	Grade 1	100	79,4
	Grade 2	17	13,5
	Grade 3	9	7,1
Metabolic Syndrome	Yes	95	75,4
	No	31	24,6

BMI: Body Mass Index, TG: Triglyceride, HDL: High-Density Lipoprotein, FBG: Fasting Blood Glucose, HbA1c: Hemoglobin A1c Hemoglobin A1c

males constituted 45.2%. The majority of participants (82.5%) were classified as obese based on Body Mass Index (BMI), and a substantial proportion (93.7%) exhibited elevated waist circumference, indicating central obesity.

Hypertension was observed in 57.9% of participants, while the remaining 42.1% were normotensive. Elevated triglyceride levels were identified in 54% of the subjects, whereas 46% had levels within the normal range. Low levels of HDL cholesterol were observed in 43.7% of participants. Regarding glucose regulation, 45.2% of participants had normal fasting blood glucose, 22.2% were pre-diabetic, and 32.5% were diabetic. Consistently, based on HbA1c values, 41.3% were classified as normal, 15.9% as pre-diabetic, and 42.9% as diabetic. All subjects presented with hepatic steatosis, of which 79.4% had grade 1, 13.5% grade 2, and 7.1% grade 3. Furthermore, 75.4% of participants met the metabolic syndrome diagnostic criteria, underscoring this cohort's comorbidity burden.

A statistically significant positive association was found between BMI and the severity of hepatic steatosis ($p = 0.031$). Among participants categorized as obese (BMI ≥ 23 kg/m^2), 16.3% had steatosis grade 2, and 8.7% had grade 3. In contrast, all individuals in the non-obese group exhibited only grade 1 steatosis, indicating that a higher BMI is significantly correlated with more severe hepatic steatosis.

Although waist circumference was elevated in most participants, its association with steatosis severity was not statistically significant ($p = 0.831$). Among high-risk individuals based on waist circumference, 13.6% had grade 2, and 6.8% had grade 3 steatosis, whereas in the low-risk group, 12.5% had grade 2 and grade 3. The lack of statistical significance suggests that waist circumference, as an isolated metric, may not reliably predict steatosis progression in this cohort.

We have established a significant relationship between steatosis severity and hypertension incidence ($p = 0.011$). Among the hypertensive subgroup, 16.4% were affected by grade 2 steatosis, while 12.3% were affected by grade 3 steatosis, compared to the normotensive group, which did not have any cases of grade 3 steatosis. This indicates that hypertension can contribute to the development of hepatic steatosis in patients with the MAFLD diagnosis.

There were no statistically significant correlations between the grade of steatosis and levels of triglyceride ($p = 0.092$), HDL cholesterol ($p = 0.198$), fasting blood glucose levels ($p = 0.575$), diabetic status ($p = 0.538$), or HbA1c levels ($p = 0.690$), although subtle trends were apparent.

On the other hand, metabolic syndrome was significantly associated with the severity of steatosis ($p = 0.021$). Metabolic syndrome patients had more significant proportions of grade 2 (16.8%) and grade 3 (9.5%) steatosis than those without the syndrome (3.2% and 0%, respectively). These observations point to the crucial role of systemic metabolic derangements in the pathogenesis and development of hepatic steatosis in MAFLD patients.

Discussion

Metabolic-associated Fatty Liver Disease (MAFLD) is closely linked with various metabolic parameters, including body mass index (BMI), waist circumference (WC), triglyceride levels (TG), hypertension (HT), high-density lipoprotein (HDL), fasting blood glucose (FBG), hemoglobin A1c (HbA1c), and metabolic syndrome [2]. This study employed the Chi-square test to determine associations between these variables and the severity of hepatic steatosis. The resulting p-values offer insight into the strength of these associations [11].

A total of 126 people were included in the assessment. Demographic analysis indicated that 45.2% of the subjects were males and 54.8% were females. While an overall higher prevalence of MAFLD is more often seen in males, the risk rises significantly in females post-menopause. Zheng et al. (2020) corroborate the argument that gender distinction is also a firm predictor of the prevalence of NAFLD. The comparatively more significant percentage of females reported in the present study could indicate the effect of hormonal changes, especially on postmenopausal women.

73.8% of the subjects were aged less than 60, and 26.2% were 60 years and above. Sánchez-Rangel et al. (2021) reported that MAFLD is more prevalent in the younger population. However, hepatic steatosis may be more apparent in elderly individuals due to decreased capacity for lipid metabolism. This aligns with the age distribution observed in the present study [12].

A population-based study in Thailand involving 34,709 individuals found a higher prevalence of non-alcoholic fatty liver disease (NAFLD) in females (22.9%) compared to males (18.3%), with the most significant disparity observed in the 56–60 age group (27.4% in females vs. 21.2% in males) [13].

Obesity emerged as the most prominent risk factor, with over 80% of the study population classified as obese. This finding reinforces earlier research by Bellentani and Marino (2017), who emphasized the strong association between obesity and hepatic steatosis. Visceral fat accumulation contributes to hepatic injury and metabolic dysregulation [12].

Waist circumference, a marker of visceral adiposity, was elevated in 93.7% of participants, indicating a high risk for hepatic fat accumulation. Ramirez et al. have highlighted the critical role of abdominal fat distribution in the pathogenesis of MAFLD [14].

Hypertension was present in 57.9% of participants. As a common component of metabolic syndrome, hypertension may exacerbate MAFLD through mechanisms involving hepatic inflammation and oxidative stress. This is supported by a meta-analysis conducted by Targher et al. (2010), which emphasized the synergistic effects of hypertension, dyslipidemia, and diabetes in accelerating hepatic injury [15].

Glycemic abnormalities were common: 22.2% of participants had prediabetes, and 32.5% had diabetes. Additionally, 42.9% exhibited elevated HbA1c levels. These findings are consistent with Bellentani and Marino (2017), who reported a strong association between type 2 diabetes and MAFLD. Chronic hyperglycemia promotes hepatic lipid accumulation, thereby increasing the risk of steatosis and disease progression [3].

Chi-square analysis revealed a statistically significant association between BMI and hepatic steatosis severity ($p = 0.031$), underscoring the central role of obesity in disease development. Elevated BMI is associated with increased hepatic lipogenesis, mainly due to insulin resistance and disruptions in lipid metabolism. Younossi et al. (2021) and Stefan et al. (2023) reported that obesity induces pro-inflammatory cytokines that exacerbate hepatic inflammation and disease progression [16]. Lim et al. (2022) also suggested

that visceral fat distribution can be a more accurate predictor of the development of MAFLD than BMI alone [17].

Obesity is also responsible for hypertriglyceridemia, which is capable of accelerating hepatic inflammation and lipid deposition. This process results in hepatocyte damage and augmented oxidative stress, as Stefan et al. (2023) explained [12]. Additionally, systemic inflammation driven by cytokines such as TNF-α and IL-6 further aggravates hepatic damage and fosters progression to metabolic-associated steatohepatitis (MASH), as Zhang et al. (2023) demonstrated [12].

Despite its known association with visceral adiposity, waist circumference did not show a statistically significant relationship with steatosis severity in this study. Although previous studies (e.g., Kim et al., 2017; Zhao et al., 2019) have found waist circumference to be a reliable indicator of MAFLD risk due to its association with insulin resistance and inflammation, the current findings suggest that waist circumference alone may not be a sufficient predictor of steatosis severity[18]. This discrepancy may be due to confounding factors or the multifactorial nature of hepatic lipid accumulation.

Hypertension, however, had a significant relationship with hepatic steatosis ($p < 0.05$). Fu et al.'s (2023) research on a population of 4,705 patients showed that hypertension alone increased the risk of hepatic steatosis (OR = 1.4; 95% CI: 1.1–1.8). High blood pressure can be a causal agent for hepatic inflammation and fibrosis, indicating the importance of comprehensive cardiovascular risk management in patients with MAFLD [19,20] .

To our surprise, triglyceride concentrations were not shown to correlate with steatosis degree substantially. Despite being a frequent finding among MAFLD patients, the transient nature of increased triglyceride levels could limit their effectiveness in predicting the degree of fat accumulation. The research conducted by Younossi et al. (2021) and Than et al. (2022) revealed that hypertriglyceridemia was more associated with fibrosis and MASH advancement than with initial fat accumulation [21].

Similarly, no statistically significant associations were found between steatosis severity and low HDL levels ($p = 0.198$), fasting blood glucose ($p = 0.575$), diabetes status ($p = 0.538$), or HbA1c ($p = 0.690$). While these factors are central

Table 2. *Correlation of Metabolic Component with Steatosis*

Variable			Steatosis			Total	Chi-Square test (p)
			Grade 1	Grade 2	Grade 3		
BMI	Obese	n	78	17	9	104	0,031*
		%	75%	16,3	8,7 %	100,0%	
	Non-Obese	n	22	0	0	22	
		%	100%	0	0	100,0%	
WC	High Risk	n	94	16	8	118	0,831
		%	79,7 %	13,6%	6,8%	100,0%	
	Low Risk	n	6	1	1	8	
		%	75%	12,5%	12,5%	100,0%	
BP	Hypertension	n	52	12	9	73	0,011*
		%	71,2%	16,4%	12,3%	100,0%	
	Non-hypertension	n	48	5	0	53	
		%	90,6%	9,4%	0,0%	100,0%	
TG	High Risk	n	51	9	8	68	0,092
		%	75,0%	13,2%	11,8%	100,0%	
	Low Risk	n	49	8	1	58	
		%	84,5%	13,8%	1,7%	100,0%	
HDL	High Risk	n	47	4	4	55	0,198
		%	85,5%	7,3%	7,3%	100,0%	
	Low Risk	n	53	13	5	71	
		%	74,6%	18,3%	7,0%	100,0%	
FBG	Normal	n	47	7	3	57	0,575
		%	82,5%	12,3%	5,3%	100,0%	
	Pre-diabetic	n	22	5	1	28	
		%	78,6%	17,9%	3,6%	100,0%	
	Diabetic	n	31	5	5	41	
		%	75,6%	12,2%	12,2%	100,0%	

Variable			Steatosis			Total	Chi-Square test (p)
			Grade 1	Grade 2	Grade 3		
DM	Yes	n	48	6	5	59	0,538
		%	81.3%	10.1%	8.6%	100%	
	No	n	52	11	4	67	
		%	77.6%	16.4%	6%	100%	
HbA1c	Normal	n	41	8	3	52	0,690
		%	78,8%	15,4%	5,8%	100,0%	
	Pre-diabetic	n	18	1	1	20	
		%	90,0%	5,0%	5,0%	100,0%	
	Diabetic	n	41	8	5	54	
		%	75,9%	14,8%	9,3%	100,0%	
Metabolic Syndrome	Yes	n	70	16	9	95	0,021*
		%	73,7%	16,8%	9,5%	100,0%	
	No	n	30	1	0	31	
		%	96,8%	3,2%	0,0%	100,0%	

BMI: Body Mass Index, WC: Waist Circumference, TG: Triglyceride, HDL: High-Density Lipoprotein, FBG: Fasting Blood Glucose, HbA1c: Hemoglobin A1c, FLI: Fatty Liver Index, *statistically significant

to the pathophysiology of MAFLD, their impact on steatosis severity may be overshadowed by more dominant factors such as obesity and hypertension. Moreover, previous studies (e.g., Petta et al., 2020; Hazlehurst et al., 2016) have suggested that these variables may be more relevant to predicting fibrosis and advanced disease rather than steatosis per se [22].

In contrast, metabolic syndrome is significantly associated with steatosis severity (p = 0.021). This finding is consistent with prior research (Younossi et al., 2021; Than et al., 2022; Stefan et al., 2023), which has established that the cumulative burden of metabolic risk factors—particularly central obesity, hypertension, and dyslipidemia—substantially increases the risk of advanced hepatic steatosis. The presence of metabolic syndrome may reflect a systemic metabolic derangement that directly drives hepatic fat accumulation and disease progression [23].

Conclusion

There are differences in the degree of steatosis in individuals with one or more metabolic risks, especially in patients who are obese and hypertensive and those with metabolic syndrome..

References

1. Carli F, Sabatini S, Gaggini M, Sironi AM, Bedogni G, Gastaldelli A. Fatty Liver Index (FLI) identifies not only individuals with liver steatosis but also at high cardiometabolic risk. Int J Mol Sci. 2023;24(19).
2. Eslam M, Sarin SK, Wong VWS, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919.
3. Yilmaz Y, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol. 2021;15(4):345-352.
4. Kuchay MS, Choudhary NS, Mishra SK. Pathophysiological mechanisms underlying MAFLD. Diabetes Metab Syndr. 2020;14:1875-1887.
5. Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389-398.
6. Liu J, Ayada I, Zhang X, et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol. 2022;20(3):e573-e582.
7. Matsubayashi Y, Fujihara K, Yamada-Harada M, et al. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex. Cardiovasc Diabetol. 2022;21(1):1-10.
8. Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases. Endocr Pract. 2022;28(5):528-562.
9. Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1.
10. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835.
11. Zhang C, Sui Y, Liu S, Yang M. Molecular mechanisms of metabolic disease-associated hepatic inflammation in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Explor Dig Dis. 2023:246-275.
12. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):155-161.
13. Thinkhamrop B, Summart U, Chamadol N, et al. Gender

differences in the prevalence of nonalcoholic fatty liver disease in the Northeast of Thailand: a population-based cross-sectional study. F1000Research. 2017;6.

14. Ramírez-Vélez R, Izquierdo M, Correa-Bautista JE, et al. Liver fat content and body fat distribution in youths with excess adiposity. J Clin Med. 2018;7(12).
15. Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2021;32(7):500-514.
16. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017;65(1):310-335. (Year inferred and journal assumed based on known citation; please confirm accuracy)
17. Lim HB, Kim DY, Kim JY. Reply. Retina. 2018;38(4):e31-e33.
18. Radmehr M, Homayounfar R, Djazayery A. The relationship between anthropometric indices and non-alcoholic fatty liver disease in adults: a cross-sectional study. Front Nutr. 2024;11:1-12.
19. Lee HW, Kim KJ, Jung KS, et al. The relationship between visceral obesity and hepatic steatosis measured by controlled attenuation parameter. PLoS One. 2017;12(10):1-12.
20. Nurul Akbar F, Dwi Bralianti P, Akbar RT, Hendarto H. Correlation between steatosis degree and hypertension degree in non-alcoholic fatty liver disease patients in Indonesia. Int J Membr Sci Technol. 2023;10.
21. Yang S, Cheng J, Zhang R, et al. Metabolic dysfunction-associated fatty liver disease and liver fibrosis: prevalence and associated factors in the middle-aged and older US population. Hepatol Res. 2022;52(2):176-186.
22. Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. Clin Gastroenterol Hepatol. 2021;19(10):2172-2181.e6.
23. Dayal U. MAFLD: exploring the systemic effects beyond liver. J Community Hosp Intern Med Perspect. 2023;15(1).